| Report Top | Up a Page | Previous | Next | Up a Map | TOC | Page Index | File Index | What's New | Page Bottom |
| Cognigen Corporation - Posters and Presentations : Cognigen Corporation : Clinical : Neoplasms Benign, Malignant and Unspecified : Posters : Topoiscmerase Inhibitors | published Wed, Nov 7, 2007 - 10:31 EST |
| Name | Description | Page Modified |
| Pharmacogenomic and Pharmacokinetic Assessment of Liposome Encapsulated SN-38 (LE-SN38) in Advanced Cancer Patients | Presented at the 2004 ASCO Annual Meeting, New Orleans, LA | Fri Nov 02 13:15:24 EDT 2007 |
| Factors Influencing the Pharmacokinetics (PK of the Anticancer Drug Irinotecan (CPT-11) and its Major Metabolites, SN-38 and SN-38G | Presented at the 2002 ACCP Annual Meeting, Albuquerque, NM | Fri Nov 02 13:15:24 EDT 2007 |
| Simultaneous Population Pharmacokinetic (PPK) Modeling of Irinotecan (CPT-11) and its Major Metabolites, SN-38 and SN-38G | Presented at the 2002 ASCPT Annual Meeting, Atlanta, GA | Fri Nov 02 13:15:24 EDT 2007 |
| Cognigen Corporation - Posters and Presentations : Cognigen Corporation : Clinical : Neoplasms Benign, Malignant and Unspecified : Posters : Topoiscmerase Inhibitors | published Wed, Nov 7, 2007 - 10:31 EST |
| Report Top | Up a Page | Previous | Next | Up a Map | TOC | Page Index | File Index | What's New | Page Top |